Dogwood Therapeutics (DWTX) Expected to Release Earnings on Wednesday

Dogwood Therapeutics (NASDAQ:DWTX) is expected to post its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.13) per share for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 10, 2026 at 12:30 PM ET.

Dogwood Therapeutics (NASDAQ:DWTX) last released its earnings results on Thursday, May 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. On average, analysts expect Dogwood Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Dogwood Therapeutics Price Performance

Shares of Dogwood Therapeutics stock opened at $1.79 on Wednesday. The firm has a market cap of $60.20 million, a price-to-earnings ratio of -0.17 and a beta of 1.71. The stock’s 50-day moving average is $1.53 and its 200-day moving average is $2.09. Dogwood Therapeutics has a one year low of $1.28 and a one year high of $9.50.

Institutional Investors Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP bought a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent quarter. 9.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on DWTX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Friday, July 24th. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Dogwood Therapeutics in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $12.00.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.